493P Impact of age on the activity of aflibercept plus FOLFIRI in metastatic colorectal cancer (mCRC): Real world data from the QoLiTrap study

Autor: M-O. Zahn, Josef Thaler, Christine Windemuth-Kieselbach, Gudrun Piringer, Sandro Anchisi, F. Scholten, R.D. Hofheinz, R. von Moos, B. Grünberger, Pierre Oliver Bohanes, Stefanie Pederiva, H. Kröning, H.-G. Derigs

Publikováno v: Annals of Oncology. 32:S574-S575

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::775169078b4fc2a2b5118495ad8cbe15
https://doi.org/10.1016/j.annonc.2021.08.1012

Impact of RAS status and prior targeted therapy on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) in daily practice. Final results of the QoLiTrap prospective non-interventional study

Autor: Roger von Moos, Felicitas Scholten, Mark-Oliver Zahn, Sandro Anchisi, Hans-Günter Derigs, H. Kröning, Josef Thaler, Stefanie Pederiva, Pierre Oliver Bohanes, Birgit Gruenberger, Christine Windemuth-Kieselbach, Gudrun Piringer, Ralf Hofheinz

Publikováno v: Journal of Clinical Oncology. 39:e15570-e15570

e15570 Background: The anti-angiogenic fusion protein aflibercept targets VEGF-A, VEGF-B and PIGF. It is approved in combination with FOLFIRI for treatment of mCRC previously treated with an oxaliplatin-containing regimen. We evaluated the influence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::31d0d9c4ad22edb2dc0fa0d316c1bd64
https://doi.org/10.1200/jco.2021.39.15_suppl.e15570

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer

Autor: Alex Powell, David N. Cade, Kenneth G. Thurston, Thomas Tichler, Navesh K. Sharma, Richard Isaacs, David Perez, Einat Shacham-Shmueli, Guy van Hazel, Paul Eliadis, Bridget A. Robinson, Michael Findlay, A. H. Strickland, Fred M. Moeslein, Tom Ferguson, Geoff Bower, H. Kröning, Javier Rodríguez, Vinod Ganju, Jens Ricke, Ido Wolf, Julien Taieb, Marc Peeters, David H. Price, Eveline Boucher, Euan Walpole, Mark Van Buskirk, Volker Heinemann, Val Gebski, Peter Gibbs

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2016, 34 (15), pp.1723-31. ⟨10.1200/JCO.2015.66.1181⟩
Journal of Clinical Oncology, 2016, 34 (15), pp.1723-31. ⟨10.1200/JCO.2015.66.1181⟩
Journal of clinical oncology

Purpose SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)–

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed87c94e681488f361650fb81a1d08a2
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01282335

Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

Autor: E. Kettner, Joerg Trojan, Florian Lordick, T. Steinmetz, Stefan Boeck, S. Zeuzem, Volker Heinemann, H. Kröning, K. Weigang-Köhler, D. Quietzsch, H. Depenbrock, O. Stotzer, C.-H. Köhne, Martin Fuchs

Publikováno v: Annals of Oncology. 18:745-751

A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC).In this multicenter phase II trial, patients with unresectable or metastatic PC who had progressed on sin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b6f1cc06144332046866596c52ebb16
https://doi.org/10.1093/annonc/mdl463

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

Autor: George Fountzilas, W. Baronius, Peter Reichardt, D. Irwin, Guenther G. Steger, Albrecht Kretzschmar, M. Biakhov, C. Slabber, T. Südhoff, A. Garin, Meinolf Karthaus, Norbert Marschner, H. Kröning, C. Giorgetti, N.G.F. Abecasis

Publikováno v: Annals of Oncology. 17:289-296

Background: Cancer patients receiving chemotherapy experience thromboembolic complications associated with the use of long-term indwelling central venous catheters (CVCs). This prospective, double-blind, placebo-controlled, multicenter study evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba2c13d8d0ec20ba6e53f75b47b03d21
https://doi.org/10.1093/annonc/mdj059